Intro To Kromite

794 views

Published on

Kromite is a consulting firm specializing in helping Life Sciences companies with tough decisions by using good decision science methods. Expertise includes facilitation, portfolio management, project valuation, sales forecasting, licensing & acquisition valuation, and risk management.

  • Be the first to comment

  • Be the first to like this

Intro To Kromite

  1. 1. The Future is Full of Possibilities<br />A consulting firm that specializes in helping Life Science companies deal with complex decisions<br />Move Beyond Base-Case Analysis<br />
  2. 2. Decision<br />Science<br />Decision Science is a discipline comprised of unique methodologies and tools whose combined output aids in making important decisions under uncertainty.<br />Decision Science is at the core of everything Kromite does<br />It’s not just an analysis, it’s a disciplined approach!<br />
  3. 3. Kromite plays three distinct roles for its clients<br />Brain<br /><ul><li>Expertise
  4. 4. Training
  5. 5. New Process Implementation
  6. 6. Process Improvement
  7. 7. Best-Practice/ Benchmark</li></ul>Hand<br /><ul><li>Staffing during peak demand
  8. 8. Outsourcing
  9. 9. Analysis
  10. 10. Modeling
  11. 11. Rush projects</li></ul>Body<br /><ul><li>Independent
  12. 12. Unbiased
  13. 13. Credible
  14. 14. Neutral
  15. 15. Objective Expert
  16. 16. Facilitator</li></ul>Industry Experience: J&J, BMS, Pfizer, Schering-Plough, Baxter, Pharmacia, & Searle.<br />Discipline Expertise: portfolio management, forecasting, decision analysis, finance, strategic marketing, & business development. <br />Industry Experience & Content Expertise: allergy/ respiratory, CNS, CV, ID, oncology, ophthalmology, pain & inflammation, urology, & virology. <br />
  17. 17. We apply Decision Science to six type of initiatives<br />Portfolio<br />Management<br />Strategy<br />Decision<br />Science<br />Sales<br />Forecasting<br />Facilitation/<br />Training<br />Licensing/<br />Merger<br />Integration<br />Asset<br />Valuation<br />
  18. 18. Our decision science expertise spans a wide range of initiatives<br />Establish portfolio management processes – Discovery, Early Development, and Full Development<br />Optimize/ prioritize portfolios:<br />One project with multiple indications<br />A product and its LCM projects<br />All projects in a therapeutic area<br />All projects in Discovery and/or Development<br />Help companies perform:<br />Portfolio preparation and data validation <br />Portfolio analysis – prioritization, optimization, resource allocation<br />Portfolio level recommendations<br />Develop therapeutic area strategy<br />Indication sequencing<br />Assess the need and priority of back-ups & second generation compounds<br />Portfolio<br />Management<br />Strategy<br />
  19. 19. Our decision science expertise spans a wide range of initiatives<br />Provide sales forecasts rather than sales prophecies<br />Forecast markets as well as products<br />Run judgmental, time series, & regression forecasts<br />Generate event-based prescription and patient forecasts<br />Develop sophisticated forecasting and valuation models that incorporate technical risk and commercial uncertainty including:<br />Monte Carlo simulation<br />Assess the impact of deal terms to balance value & risk<br />Evaluate potential partner’s product/pipeline<br />Combine R&D portfolios & prioritize projects after a merger<br />Help “alliances” prioritize activities as an independent party<br />Sales<br />Forecasting<br />Licensing/<br />Merger<br />Integration<br />
  20. 20. There are a number of additional strengths and benefits we provide our clients<br />Proven track record<br />Collaborated with top pharma companies<br />Worked with mid and small sized biopharma and private equity companies<br />Our staff developed and/or led portfolio management processes across a range of companies before joining Kromite: J&J, BMS, Pfizer, Schering-Plough, Pharmacia, Baxter Biosciences, and Searle<br />Extensive data gathering expertise<br />Subscriptions: IDdb, Thompson Pharma, and Dialog<br />Routinely search: Clinicaltrials.gov, Orange Book, and Medscape <br />Validated forward looking benchmarks<br />R&D cost, Probability of success, commercial costs & financial ratios<br />Sophisticated models that are user-friendly and client compatible<br />Exceptional ability to facilitate cross functional alignment<br />
  21. 21. Appendix<br />
  22. 22. Kromite Senior Management:Homie Razavi, Ph.D., MBA<br />Homie Razavi has over fifteen years of experience in the industry with a decade of experience in decision analysis, project and portfolio evaluation/assessment. Prior to founding Kromite, he was in charge of the Portfolio Management and Valuation group at Pharmacia with responsibility for analyzing individual pipeline projects as well as the portfolio management processes. His team worked on over 80 projects, with an R&D spending of $2 billion annually, in a number of therapeutic areas: inflammation/ arthritis, oncology, ophthalmology, urology, CNS and anti-infective. At Searle Pharmaceuticals, he helped establish and lead the portfolio management activities in the Discovery organization with 30 projects worth over $30 billion. In addition, he was responsible for helping oncology and cardiovascular teams evaluate decisions and assess the risk of different strategies. <br />During his tenure at Kromite, he has helped a broad spectrum of companies with their portfolio processes, project assessments and the improvement of the quality and speed of their decision making, through facilitated meetings. <br />He has a broad management background, with experience in business and commercial development as well as R&D. He holds a Ph.D. in Chemistry from the University of Colorado and an MBA from Washington University. <br />
  23. 23. Kromite Senior Management:Jack M. Kloeber Jr., Ph.D.<br />Jack Kloeber is a retired US Army Lieutenant Colonel with experience in R&D portfolio management, decision analysis, modeling and simulation, technology selection, and strategy development. Jack taught mathematics at West Point for 3 years and graduate level decision analysis, systems simulation, and technology selection for 6 years at the Air Force Institute of Technology. <br />His work has supported decisions for various superfund sites within the Department of Energy, and many technology organizations within the Departments of Army, Air Force, and Navy. He is widely published (in 8 different Decision Support journals).<br />Jack was the head of Portfolio Management for Bristol-Myers Squibb. More recently, he was the head of the Portfolio Management for J&J Pharma Services where he coordinated the portfolio management efforts for J&J Pharmaceuticals across multiple R&D and marketing operating companies. <br />He received his PhD in Economic Decision Analysis from Georgia Institute of Technology and Masters in Industrial Engineering from Lehigh University.<br />

×